Navigation Links
Neuralstem Grants Licenses For Central Nervous System Therapy Surgical Devices To Cedars-Sinai Medical Center
Date:2/20/2013

ROCKVILLE, Md., Feb. 20, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that it has granted licenses to intellectual property surrounding its spinal cord delivery platform, floating cannula, and method for delivering therapeutic agents to the spinal cord to Cedars-Sinai Medical Center, a non-profit academic medical center located in Los Angeles, CA. The license agreements grant Cedars-Sinai Medical Center the non-exclusive right to use the licensed intellectual property in academic research. This is the second group of licenses announced by Neuralstem for these technologies. The financial terms of the agreement were not disclosed. Neuralstem holds the exclusive worldwide licenses to the platform and cannula technologies. 

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO)

The platform and cannula have been used since 2010 in a Phase I ALS trial, sponsored by Neuralstem and recently completed at Emory University, covering the delivery of Neuralstem's NSI-566 neural stem cells into the spinal cords of patients with amyotrophic lateral sclerosis (ALS or Lou Gehrig 's disease). Neuralstem recently received FDA approval to commence a Phase I trial in chronic spinal cord injury using the platform and cannula technologies.

"This second set of licenses for our devices further demonstrates the growing acceptance of intraspinal delivery of therapeutics, once thought impossible, in the treatment of spinal cord conditions and diseases," said Richard Garr , Neuralstem's President and CEO. "We have shown that it can be done safely in our ALS trial in 15 patients, and 18 procedures, in which three patients successfully returned for second transplants. We plan to continue our licensing program to industry and academia as they begin to explore the possibilities our technology has enabled."

About Neuralstem

Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem completed dosing of the last patient in an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig 's disease, in August 2012; the trial ends six months after that last surgery. Neuralstem has been awarded orphan status designation by the FDA for its ALS cell therapy.

In addition to ALS, the company is also targeting major central nervous system conditions with its NSI-566 cell therapy platform, including spinal cord injury, ischemic stroke and glioblastoma (brain cancer). The company received approval to commence a Phase I safety trial in chronic spinal cord injury in January 2013.

Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions.  The company is in a Phase Ib safety trial evaluating NSI-189, its first neurogenic small molecule compound, for the treatment of major depressive disorder (MDD). Additional indications could include chronic traumatic encephalopathy (CTE), Alzheimer's disease, and post-traumatic stress disorder (PTSD).

For more information, please visit www.neuralstem.com or connect with us on Twitter, Facebook and LinkedIn

Cautionary Statement Regarding Forward Looking Information

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem's periodic reports, including the annual report on Form 10-K for the year ended December 31, 2011 and the quarterly report on Form 10-Q for the period ended September 30, 2012.

 


'/>"/>
SOURCE Neuralstem, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Neuralstem Updates ALS Stem Cell Trial Progress
2. Sixteenth Patient Dosed In Neuralstem ALS Stem Cell Trial
3. First Patients Dosed in Ib Phase of Neuralstems NSI-189 Trial in Major Depressive Disorder
4. Seventeenth Patient Dosed in Neuralstem ALS Stem Cell Trial
5. Neuralstem Announces Exercise Of Entire Over-Allotment Option By Aegis Capital Corp.
6. Neuralstem Grants First Licenses For CNS Therapy Surgical Devices
7. Neuralstem Announces Proposed Public Offering
8. Neuralstem to Raise $7.0 Million in Registered Direct Offering
9. Neuralstem President And CEO To Present At BIO CEO & Investor Conference 2013
10. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
11. Community Foundation Announces $2.6 Million In Grants From Centinela Medical Funds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2017)... , Aug. 2, 2017   Marshall County Hospital in Benton, Kentucky ... reduce the risk of hospital-acquired infections (HAIs). The new addition, Tru-D SmartUVC , short ... to kill deadly pathogens such as C. diff , MRSA, MERS, Ebola and more. ... Tru-D SmartUVC ... Tru-D in action in a patient room ...
(Date:8/2/2017)... a next-generation full-service pharmacy, has announced the launch of its ... Washington D.C. metropolitan area. CaryRx aims to ... through the convenience of its patient-friendly mobile app. Prescriptions can ... to any location in D.C. ... Washington D.C. ," says Areo Nazari , ...
(Date:7/31/2017)... 31, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), has been ... Michigan by Crain,s Detroit Business . ... companies by three-year revenue growth. This year,s edition measures growth ... To view the complete list, visit crainsdetroit.com/awards/fast_50/2017 .  ... incredible triumph," said Phil Hagerman , CEO and chairman ...
Breaking Medicine Technology:
(Date:8/23/2017)... ... August 23, 2017 , ... Silicon Valley Hair Institute, a leading San ... organized month-by-month. The new rotation of archived blog posts can provide a wide selection ... about hair transplantation can review details online and then reach out for a no ...
(Date:8/23/2017)... ... August 23, 2017 , ... The non-profit Seafood Nutrition ... inaugural State of the Science Symposium in partnership with the Global Organization for ... This symposium provides a forum for global leaders in human nutrition to outline ...
(Date:8/22/2017)... LAS VEGAS, NEV. (PRWEB) , ... August 22, ... ... the American Academy of Anti-Aging Medicine recently spoke at a popular international aesthetics ... laser therapy has had on restoring his patients’ health and his growing practice. ...
(Date:8/22/2017)... (PRWEB) , ... August 22, 2017 , ... Nurses at ... acres at picturesque Babcock Cove, recently received training and certification in Closed Pulse ... which has a prestigious five-star rating from the Centers for Medicare and Medicaid Services, ...
(Date:8/22/2017)... ... August 22, 2017 , ... ... of child abuse and neglect, and the struggles faced while hoping for a ... creation of published author, Judy Von Bernewitz, who spent 13 years working with ...
Breaking Medicine News(10 mins):